Thelansis

 Head and neck squamous cell carcinoma (HNSCC) presents a multifaceted challenge for clinicians due to its complexity. Recent understanding attributes human papillomavirus (HPV) infection as the primary cause, particularly in oropharyngeal squamous cell carcinoma (OPSCC), which constitutes approximately 60–70% of cases. While the majority of HNSCC patients are diagnosed at a stage amenable to definitive therapy, about 10% present with distant metastases. Notably, a significant portion of patients, particularly those with HPV-negative HNSCC, experience recurrence. Unfortunately, recurrent or metastatic HNSCC carries a bleak prognosis, with median survival ranging from 12 to 15 months despite treatment efforts. The standard approach involves a multidisciplinary strategy incorporating surgery, chemotherapy, and radiotherapy, primarily targeted towards locally advanced diseases.   Thelansis’s “Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology, Competi

 Head and neck Squamous cell carcinoma (HNSCC) is a complex group of malignancies, posing several challenges to treating physicians. Most patients are diagnosed with locally advanced diseases and treated with strategies integrating surgery, chemotherapy, and radiotherapy. About 50% of these patients will experience a recurrence of the disease. Recurrent/metastatic HNSCC have a poor prognosis with a median survival of about 12 to 15 months despite treatments. Head and neck cancer is the seventh most common cancer worldwide, accounting for 3% of all cancers, with approximately 900,000 new cases and half a million deaths. ·        Human papillomavirus infection is now recognized as the major causative agent for HNSCC, especially in the oropharynx (OPSCC), accounting for approximately 60–70% of OPSCC in the United States. ·        HPV(+) HNSCC shows marked differences in epidemiology and pathophysiology as compared to HPV unrelated or negative (−) HNSCC. ·        Demographically, HPV